Calcium acetate does not appear to increase the risk of cardiovascular calcinosis over sevelamer
- PDF / 136,250 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 63 Downloads / 213 Views
1
■ Calcium acetate does not appear to increase the risk of cardiovascular calcinosis over sevelamer, if lipid levels are maintained, according to results of a study presented at the American Society of Nephrology’s Renal Week 2006. In the Calcium Acetate Renagel Evaluation (CARE-2) study, patients were randomised to receive calcium acetate [PhosLo] or sevelamer [Renagel], in addition to atorvastatin [Lipitor] if required to control LDL-cholesterol levels. After 12 months, there was no statistically significant between-treatment difference in the progression of cardiovascular calcinosis. According to Fresenius, these data refute the hypothesis that the calcium in PhosLo may contribute to cardiovascular calcinosis. Fresenius Medical Care AG. Fresenius Medical Care Announces Positive Results from PhosLo CARE-2 Study. Media Release : 21 Nov 2006. Available 809070007 from: URL: http://www.fmc-ag.com
0114-9954/10/1130-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 2 Dec 2006 No. 1130
Data Loading...
